Kura Oncology officer proposes $148K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. (KURA) lists a Form 144 notice by officer Mollie Leoni for a proposed sale of 19,009 common shares, with an aggregate market value of $147,699.93 and an approximate sale date of November 16, 2026. The shares are listed as acquired from the issuer through a PSU transaction on November 13, 2026.
During the preceding three months, the notice lists a sell-to-cover sale of 12,448 performance-based restricted stock units on September 28, 2026, for gross proceeds of $130,670.39, and 28,802 units in an entry labeled 10b5-1 Sales on September 29, 2026, for gross proceeds of $309,565.84. The listed number of common shares outstanding is 92,784,785. Teresa Bair signed as attorney-in-fact for Mollie Leoni.
Key Figures
Key Terms
Performance-Based Restricted Stock Units financial
sell-to-cover financial
10b5-1 Sales regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior KURA stock sales did Mollie Leoni report?
AI-generated analysis. How Rhea-AI works. Not financial advice.